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Malaria parasites engage a multitude of strategies to evade the immune system of the
host, including the generation of polymorphic T cell epitope sequences, termed altered
peptide ligands (APLs). Herein we use an animal model to study how single amino acid
changes in the sequence of the circumsporozoite protein (CSP), a major target antigen
of pre-erythrocytic malaria vaccines, can lead to a reduction of cross reactivity by T cells.
For the first time in any APL model, we further compare different inflammatory adjuvants
(Montanide, Poly I:C), non-inflammatory adjuvants (nanoparticles), and peptide pulsed
dendritic cells (DCs) for their potential capacity to induce broadly cross reactive immune
responses. Results show that the capacity to induce a cross reactive response is
primarily controlled by the T cell epitope sequence and cannot be modified by the use
of different adjuvants. Moreover, we identify how specific amino acid changes lead to a
one-way cross reactivity: where variant-x induced responses are re-elicited by variant-x
and not variant-y, but variant-y induced responses can be re-elicited by variant-y and
variant-x. We discuss the consequences of the existence of this one-way cross reactivity
phenomenon for parasite immune evasion in the field, as well as the use of variant
epitopes as a potential tool for optimized vaccine design.
Keywords: circumsporozoite protein, CD8 epitope, altered peptide ligands, polymorphism, cross reactivity,
vaccines
INTRODUCTION
Immune evasion by parasites is a major obstacle to overcome for vaccine development. One of
the mechanisms employed by malaria parasites is the development of variant epitope sequences,
termed altered peptide ligands (APLs). APLs contain multiple or single amino acid changes that
can affect their immunogenicity or ability to be recognized by pre-existing immune responses
(Plebanski et al., 1997). There are many different APLs in regional populations of parasites, and
one possible way to increase cross reactive immunity to APL epitopes is through vaccine design
against multiple variant antigens.
Vaccines to malaria, including the recently approved RTS,S (Mosquirix) vaccine, tend
to focus on the pre-erythrocytic stage of malaria to prevent infection progressing to
the clinically symptomatic erythrocytic stage (Duffy et al., 2012). Liver stage malaria
infection by sporozoites would benefit from a CD8 T cell response to eliminate parasitized
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hepatocytes (Doolan and Martinez-Alier, 2006). Eliciting such a
CD8 T cell response is a challenge for vaccine design in particular
due to the inability of most adjuvants to induce high levels of
CD8 T cells. Furthermore, in addition to high levels of CD8 T
cell responses, prospective malaria vaccines would need to induce
broad cross reactivity to multiple variant epitopes to ensure
protective immunity.
Vaccine adjuvants have the capacity to enhance recognition,
and potentially cross reactivity, to vaccine antigens. Nonetheless,
this question has not been widely addressed experimentally as yet
in any vaccine model. Traditionally adjuvants enhance immune
responses by eliciting inflammatory cytokine production. Whilst
the most common adjuvant, Alum, induces Th2 biased responses
(McKee et al., 2009), certain inflammatory type experimental
adjuvants, such as the water-in-oil emulsion, Montanide, and the
toll like receptor 3 (TLR3) agonist, Poly I:C, are well regarded
for their ability to elicit CD8 T cells to short peptide epitopes
(Aucouturier et al., 2002; Elliott et al., 2008; Herrera et al., 2011;
Cho et al., 2013). However, not all adjuvant systems need to
induce inflammatory cytokines to elicit potent responses. Ex
vivo peptide pulsed DCs are naturally immunogenic, and do
not require the addition of an adjuvant, as they can be directly
loaded ex vivo with peptides and transferred back to a host,
to induce substantial immune responses. Furthermore, novel
polystyrene nanoparticles (PSNPs), in the viral size range of 40–
50 nm, with covalently bound peptide are capable of inducing
robust CD8 T cell responses, in the absence of conventional
inflammatory signals (Xiang et al., 2013). In our previous studies
the non-inflammatory PSNP vaccines induced comparable levels
of CD8 T cell immune responses to peptide delivered with
the inflammatory adjuvant Montanide (Wilson et al., 2015).
Alongside adjuvant selection, target antigen choice for vaccines is
an important consideration for the induction of optimal antigen-
specific immunity.
One such target antigen for Plasmodium falciparum liver
stage malaria vaccine development, the circumsporozoite protein
(CSP), displays a wide range of APL variant epitopes. CSP
from P. falciparum contains two main variable T cell regions,
T helper region 2 and 3 (Th2R and Th3R), both of which
contain highly polymorphic nested CD4 and CD8 T cell
epitopes (Plebanski et al., 1997). In the case of the human
leukocyte antigen B35 (HLA-B35) binding region within Th3R,
only two of the multiple polymorphic variants bind major
histocompatibility complex (MHC) molecules, and naturally
induced CD8 T cell reactivity to these two variants is not
cross reactive (Gilbert et al., 1998; Plebanski et al., 1999). The
current leading pre-erythrocytic vaccine, RTS,S induces CD4
but not CD8 T cells in humans (Lalvani et al., 1999; Reece
et al., 2004). It is relevant to note that this vaccine showed
better efficacy against the parasites in the population bearing
the allelic variant of CSP also present in the vaccine (Neafsey
et al., 2015), highlighting the importance of considering antigen
polymorphism during vaccine design. Polymorphic antigens
pose numerous problems, however, for complex pathogens,
such as malaria, polymorphic antigen candidates may not
be easily avoided. Therefore, devising strategies to overcome
immune evasion and complications with polymorphic antigens
for vaccine design is an important question to address in this
field.
Mouse models of variant epitopes are a useful tool to
understand and demonstrate the impact of amino acid changes
to T cell epitopes, even though these epitopes cannot be
directly used in human vaccines. The known protective
immunodominant CD8 T cell epitope of the murine strain
P. berghei CSP is SYIPSAEKI (also named pb9, or KI). Notably,
position 8 along this peptide has been shown to be an important
position for T cell recognition and T cell activation (Maryanski
et al., 1993; Kessler et al., 1998), and thus an important residue to
study the impact of potential variant amino acid changes. Herein,
we show that single amino acid changes to the T cell receptor
(TCR) contact residue, position 8 (lysine), of the SYIPSAEKI
epitope can lead to a loss of recognition by T cells. We further
assess the impact of utilizing diverse adjuvants, representing both
inflammatory and non-inflammatory adjuvant systems, to affect
the magnitude and breadth of cross-reactivity of the immune
responses.
MATERIALS AND METHODS
Animals
BALB/c mice (6–8 weeks old) were purchased from Monash
Animal Services (MAS, Melbourne, VIC, Australia). All animals
were used under ethics approval by the Alfred Medical Research
and Education Precinct (AMREP) Animal Ethics Committee.
Ex Vivo DC Pulsing with Peptide
Hematopoietic stem cells were harvested from the femur and
tibia of BALB/c mice, and seeded at 0.5× 106 cells/ml in complete
media (CM) containing RPMI 1640 supplemented with 10%
fetal calf serum (FCS, Gibco, Life Technologies), 100 units/ml
penicillin, 100 µg/ml streptomycin (Gibco), 2 mM L-Glutamine
(Gibco), 1 M Hepes, and 0.1 mM 2-mercaptoethanol (Sigma–
Aldrich, St Louis, MO, USA), and additionally a final of 10 ng/ml
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
(PeproTech, Rocky Hill, NJ, USA) and 5 ng/ml Interleukin 4
(IL-4) for 6 days (note that half of the media was replaced with
replenished cytokines on day 3) to induce the differentiation
of DCs. On day 6, DCs were pulsed with 5 µg/ml SYIPSAEKI
peptide for 1–2 h in the same culture media, and then washed
with phosphate buffered saline (PBS) and re-suspended at 1× 107
cells/ml in PBS for immunizations.
Peptide Conjugation to Nanoparticles
Nanovaccine formulations were prepared by conjugation of
peptides SYIPSAEKI, SYIPSAERI, SYIPSAEVI, SYIPSAEAI,
SYIPSAEEI, or SYIPSAEDI to carboxylated PSNPs (Polysciences
Inc., Warrington, PA, USA) based on the previously outlined
method (Xiang et al., 2013; Wilson et al., 2015). Briefly, PSNPs
(∼40–50 nm) at a final of 1% solids were activated using a 2-N-
morpholino-ethanesulfonic acid (MES; 50 mM final, pH = 7)
buffered solution of 1-ethyl-3-(3-dimethylaminopropryl)
carbodiimide hydrochloride (EDC; 4 mg/ml final, Sigma–
Aldrich), together with the malaria peptides (SYIPSAEKI or the
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variants SYIPSAERI, SYIPSAEVI, SYIPSAEAI, SYIPSAEEI, and
SYIPSAEDI, Mimotopes, Melbourne, VIC, Australia; 1 mg/ml
final) on a rotary wheel, for 4 h at room temperature (RT).
Following incubation, the conjugation reaction was stopped
and unbound reactive sites coated by the addition of glycine
(7 mg/ml final, Sigma–Aldrich) and further incubated as above
for 30 min. Unconjugated peptide and excess glycine and other
reagents were removed by dialysing in dialysis membrane (10–
14 kDa molecular weight cutoff; Viskase, Darien, USA), against
PBS (pH = 7.2–7.4) overnight at 4◦C. Conjugation efficiency
was determined by Bicinchoninic Assay (BCATM; Thermo
Fisher Scientific, Rockford, IL, USA) following manufacturer’s
instruction. Final size of the formulation was determined
by dynamic light scattering instruments (Zetasizer; Malvern
Instruments, Worcestershire, UK).
Vaccine Adjuvants and Immunizations
Vaccines consisted of the following formulations in PBS;
SYIPSAEKI (final 5 µg/ml) pulsed DCs (1 × 106 cells/mouse
in 100 µl PBS) with or without the addition of PSNPs (50 µl
at 2% solids mixed in); SYIPSAEKI (final 25 µg/mouse) mixed
with the adjuvants Montanide ISA 720 (70% v/v with PBS;
Tall Bennet Group, USA), or Polyinosinic-polycytidylic acid
sodium salt (Poly I:C; 25 µg/mouse final, Sigma–Aldrich).
Nanovaccines contained either SYIPSAEKI (∼25 µg/mouse)
simply mixed with PSNPs (∼1% final solids), or peptides
covalently conjugated to the PSNPs, including SYIPSAEKI
or the variant peptides SYIPSAERI, SYIPSAEVI, SYIPSAEAI,
SYIPSAEEI, and SYIPSAEDI (target 25 µg/mouse, ∼0.65–
1.47% final solids to achieve target peptide loading per mouse).
Mice were immunized with respective formulations, either
once, or twice, 2 weeks apart, intradermally at the base of
tail. Approximately 13–14 days after the last immunization
(unless otherwise stated) mice were humanely euthanized and
splenocytes harvested and assessed for IFN-γ production by
ELISpot assay.
ELISpot
Antigen specific and cross reactive CD8 T cell responses were
assessed by IFN-γ ELISpot assay. Ninty-six well multiscreen
plates (MSIP; Millipore, Billerica, USA) were coated with 5µg/ml
anti-mouse IFN-γ (AN18; MABTech, Stockholm, Sweden),
100 µl/well in PBS, and incubated at 4◦C overnight. Following
incubation, all wells were washed five times with PBS and
blocked with CM for a minimum of 1 h at 37◦C. Splenocytes
harvested from immunized mice were added to wells in triplicate
(1 × 107 cells/ml, 50 µl/well), and co-incubated with the
different recall antigens (SYIPSAEKI, SYIPSAERI, SYIPSAEVI,
SYIPSAEAI, SYIPSAEEI, SYIPSAEDI; Mimetopes, Melbourne,
Australia; final 2.5 µg/ml), as well as a media alone control,
and concanavalin A (ConA; Amersham Biosciences, Uppsala,
Sweden; final 1 µg/ml) as positive control. Splenocytes and
antigens were co-incubated in CM at 37◦C, with 6% C02 for 12–
16 h. Following incubation, plates were washed with PBS and the
anti-IFN-γ biotinylated detection antibody was added (R4-6A2-
biotin, MABTech; 1 µg/ml final in PBS/0.5% FCS), 100 µl/well,
and incubated at RT for 2 h. Plates were washed as above before
addition of streptavidin-alkaline phosphate enzyme conjugate
(ALP; final 1 µg/ml in PBS/0.5% FCS), 100 µl/well, for 1.5 h at
RT. Plates were washed with PBS as above and given a final wash
with reverse osmosis (RO) water. Spots were developed using an
AP colorimetric kit (Bio-Rad, Philadelphia, PA, USA), following
manufacturer’s instructions. Plates were left to dry overnight at
RT before spots were counted using an AID ELISpot reader
system (AutoImmune Diagnostika GmbH, Germany).
Binding Assay
For determination of peptide binding ability to MHC class
I (MHCI) (H2-Kd), a binding assay using a MHCI (H2-Kd)
transfected RMA-S cell line was performed. Briefly, RMA-S-Kd
cells were cultured in CM further supplemented with 0.8 mg/ml
G418 disulphide salt (Sigma–Aldrich), until confluent. Cells were
seeded into 48 well plates (0.5 × 106 cells/ml) and incubated
at 28–29◦C overnight with 6% C02, allowing cells to express
H2-Kd. Following incubation peptides (SYIPSAEKI, SYIPSAERI,
SYIPSAEVI, SYIPSAEAI, SYIPSAEEI, and SYIPSAEDI) were
added in triplicate wells (at final concentrations of 0, 0.025, 0.25,
and 2.5 µg/ml), and further incubated at 28–29◦C with 6% C02
for 1 h. Plates were then transferred to 37◦C, 6% C02, for an
additional 3 h so that empty H2-Kd molecules could be recycled.
Cells were transferred to 96 well ‘V’ bottom plates for flow
cytometry staining and stained with biotinylated anti-H2-Kd
mAb (clone SF1-1.1; Biolegend, San Diego, CA, USA), or isotype
control biotinylated anti-mouse IgG2aκ (Biolegend), at pre-
determined dilutions, in PBS/2% FCS (30 µl/well) for 15 min at
RT. Following incubation cells were washed with PBS/2% FCS
(100 µl/well), and centrifuged before addition of streptavidin-
AF700 (Thermo-Fisher) in PBS/2% FCS (30 µl/well) for 15 min
at RT. Stained cells were given a final wash with PBS/2%
FCS and fixed with 1% (v/v) paraformaldehyde (PFA; Sigma–
Aldrich). Cells were acquired using an LSRII flow cytometer (BD
Biosciences, USA), located at the AMREP Flow Cytometry Core
Facility (Melbourne, Australia). Data was analyzed using FlowJo
software (version 10; Treestar, USA).
Statistics
Statistical analysis was conducted using two way analysis of
variance (ANOVA), with post hoc Dunnetts (or Tukey where
applicable), multiple comparison tests, using Graphpad Prism
software (v.6. San Diego, CA, USA). Statistical significance was
set as p < 0.05. Values are expressed as mean ± standard
deviation (SD), and group sizes are indicated in the figure
legends.
RESULTS
Ex Vivo Peptide Pulsed DCs as Natural
Adjuvants Induce Low Levels of Cross
Reactivity to APLs of the CD8 Epitope
SYIPSAEKI
APLs of the P. berghei immunodominant CD8 T cell epitope
SYIPSAEKI (herein termed KI) were created by substituting
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FIGURE 1 | Cross reactivity to APLs when adjuvanted by KI pulsed DCs, with or without nanoparticles (PSNPs) co-injection. BALB/c mice were
immunized once with naïve control (PBS alone), DCs alone (1 × 106 cells in PBS), or peptide pulsed DCs (1 × 106 cells pulsed with 5 µg/ml KI, DCs/KI), with or
without co-injected PSNPs (1 × 106 cells pulsed with 5 µg/ml KI co-injected with a final 0.67% PSNPs, DCs/KI + PSNPs). Thirty five days after the immunization
splenocytes were harvested and antigen specific or cross reactive IFN-γ production was measured via ELISpot assay. Data shown as mean ± SD of SFU/million
cells (pooled cells from four mice per group) from triplicate wells. ∗∗p < 0.01, ∗∗∗∗p < 0.0001, ####p < 0.0001 between DCs/KI and DCs/KI + PSNPs groups.
the lysine at position 8 with amino acids carrying different
charges. Five altered peptides were created; SYIPSAERI (RI),
arginine substitution at position 8; SYIPSAEVI (VI), valine
substitution; SYIPSAEAI (AI), alanine substitution; SYIPSAEEI
(EI), glutamic acid substitution; and SYIPSAEDI (DI), aspartic
acid substitution. Additionally, the substituted amino acids alter
the charge of the position 8 amino acid, KI and RI carry a
positive side chain charge, VI and AI carry a neutral side chain
charge, and EI and DI carry a negative side chain charge. Notably,
side chain charge may not alter substantially the overriding
charge of the peptide. Cross reactivity to these APLs was initially
examined using various adjuvant systems immunized with the
index peptide KI.
Ex vivo peptide pulsed DCs are naturally immunogenic
and are advantageous due to their ability to effectively prime
antigen specific T cells, without requiring an additional
adjuvant. Bone marrow was extracted from BALB/c mice and
cultured for 6 days, with the cytokines GM-CSF and IL-4,
and cultured DCs were pulsed with KI for 1–2 h prior to
immunization (DCs/KI). Previous studies have shown that non-
inflammatory nanoparticles (PSNPs) further enhance immune
responses when mixed with micro-particulate vaccines (Fifis
et al., 2004; Xiang et al., 2015). Therefore, KI pulsed DCs were
additionally co-injected with PSNPs alone (DCs/KI + PSNPs),
to examine if a potential similar enhancement would also
have an effect on the pattern of cross reactivity to APL
variants. BALB/c mice were immunized, once with the above
formulations, and 35 days after the immunization splenocytes
were harvested and analyzed for IFN-γ production via ELISpot
assay.
Figure 1 shows that KI pulsed DCs induced significantly
higher levels of KI specific IFN-γ to the peptide itself, compared
to the media alone control (p < 0.0001, Figure 1), and a
moderate level of cross reactivity to the other APL variants, in
particular significant responses above media for RI (p < 0.0001),
and VI (p < 0.01). The ranking of APL responses showed
that RI (positive charge at position 8, the same charge as
the lysine in KI) was the most cross reactive, followed by
VI and AI (neutral charge at position 8), with EI and DI
(negative charge at position 8) the least cross reactive to the
index peptide KI (Figure 1). Interestingly, KI pulsed DCs co-
injected with PSNPs showed significantly higher KI specific
IFN-γ responses for all peptides, apart from media alone,
compared to the DCs/KI group (p < 0.0001 for each peptide),
as well as significantly increased magnitude of responses,
compared to media, to all five cross reactive APLs tested
(p < 0.0001 for all APLs). Notably, the pattern of IFN-
γ response to the APLs remained the same, suggesting that
PSNPs may not be directly affecting the breadth of the T
cell response, but may enhance the number of reactive T
cells, which could proportionally enhance the magnitude of
responses.
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FIGURE 2 | Binding ability of the index peptide, KI, or APLs to the MHC
molecule H2-Kd. H2-Kd transfected RMA-S cells were cultured in vitro
overnight to allow expression of the MHC, and subsequently co-cultured KI,
or with each of the altered peptides, in triplicate at three different
concentrations, for peptide-MHC complex stabilization at the cell surface.
Cells were stained with anti-mouse H2-Kd and the mean fluorescent intensity
(MFI) of H2-Kd for each condition was determined (0 is equivalent to the MFI
for RMA-S-H2-Kd cells alone). Data shown as MFI of H2-Kd expression (Ratio
of peptide pulsed cells over cells alone) ±SD from triplicate wells. Dotted line
represents the index peptide KI.
Limited APL Cross Reactivity is not a
Consequence of Lack of Peptide Binding
to MHCI
The low level of cross reactive responses to certain epitopes,
particularly DI and EI, could be explained if these APL variants
had a lower binding capacity to MHCI than KI. To assess this
formally, we performed a binding assay which utilizes the cell
line, RMA-S, deficient in MHCI loading molecules, which has
been transfected with H2-Kd, creating a cell line reported to
have a heat sensitive expression of MHCI. In temperature ranges
of 26–30◦C H2-Kd is expressed on the cell surface, allowing
peptide binding and stabilization of the peptide-MHC complex
(Ljunggren et al., 1990; Rock et al., 1992). At higher temperatures
(37◦C) empty MHC molecules start to be recycled back into
the cell, unless they are stabilized on the surface by exogenously
binding peptide. Detection of surface peptide-MHCI complexes
is achieved through flow cytometry staining for H2-Kd. Of
interest to this study was the relative comparison of peptide
binding ability of the APLs to the index peptide, KI. As can be
seen in Figure 2, all variant peptides achieved an equal, or greater,
level of binding compared to KI at all three concentrations of
peptide loading tested (0.025, 0.25, and 2.5 µg/ml). This suggests
that the limited cross reactive responses observed were not due to
a lack of binding ability to MHCI for these variant peptides.
The Adjuvant Montanide Elicits a Similar
Pattern of Cross Reactivity Compared to
Peptide Pulsed DCs
A high magnitude of antigen specific IFN-γ responses have
previously been shown to the KI peptide in vivo by using
the conventional inflammatory adjuvant Montanide, with lower
responses inducible with Poly I:C (Wilson et al., 2015). To
examine the cross reactivity of the five APLs mentioned above
we examined the responses induced using Montanide or Poly
I:C as the vaccine adjuvant. BALB/c mice were immunized either
once, or twice, with the peptide alone (KI alone), or mixed with
Montanide or Poly I:C (Montanide + KI and Poly I:C + KI,
respectively), and 14 days after the last immunization IFN-γ
production was assessed via ELISpot assay.
After one immunization (Figure 3A), Montanide + KI
induced the highest IFN-γ production to the index epitope, KI,
significantly higher compared to the media alone background
(p < 0.0001). Furthermore, moderate compared to KI, but
FIGURE 3 | Cross reactivity to APLs of the peptide SYIPSAEKI induced by the conventional adjuvants Montanide or Poly I:C. BALB/c mice were
immunized once (A), or twice (B) with KI peptide alone (25 µg /mouse), or mixed with Montanide (25 µg peptide mixed with 70% v/v Montanide in PBS /mouse,
Montanide + KI) or Poly I:C (25 µg peptide and 25 µg Poly I:C /mouse, Poly I:C + KI). Fourteen days after the last immunization splenocytes were harvested and
antigen specific or cross reactive IFN-γ production was measured via ELISpot assay. Data shown as mean ± SD of SFU/million cells (pooled cells from 3 to 4 mice
per group) from triplicate wells. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001
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FIGURE 4 | Cross reactivity to APLs of the peptide SYIPSAEKI induced by nanovaccine systems. BALB/c mice were immunized once (A), or twice (B) with
KI peptide alone, or either mixed with, or conjugated to, PSNPs (25 µg peptide, 1% PSNPs /mouse for both mixed in and conjugated groups). Fourteen days after
the last immunization splenocytes were harvested and antigen specific or cross reactive IFN-γ production was measured via ELISpot assay. Data shown as
mean ± SD of SFU/million cells (pooled cells from three mice per group) from triplicate wells. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001
significant, cross reactivity was seen with this group to the APLs
RI and VI (p < 0.0001), as well as to AI (p < 0.01), similar to
the pattern observed with ex vivo pulsed DCs. Poly I:C+ KI only
induced significant levels of IFN-γ response to KI (p < 0.0001),
showing a corresponding decreased ability to induce detectable
cross reactive T cells. A further boost immunization displayed
a similar pattern of results for the Montanide + KI group, with
a significantly high amount of KI specific CD8 T cell responses
(p< 0.0001), and low to moderate cross reactivity to the APLs, in
particular significant cross reactivity to RI (p < 0.0001), and VI
(p< 0.01), with overall magnitude of responses lower, but ranked
similar, compared to one immunization (Figure 3B). The boost
immunization did not enhance responses induced by the Poly
I:C+ KI group.
Conjugated PSNPs Induce Little Cross
Reactivity to APLs of the CD8 Epitope
SYIPSAEKI
Previously it has also been observed that peptide conjugated to,
but not mixed with, PSNPs induces high levels of KI specific
CD8 T cell responses (Wilson et al., 2015). Following this, cross
reactivity to APLs of KI were investigated after one or two
immunizations with KI mixed with, or conjugated to, PSNPs.
After one immunization, there were low numbers of KI specific
CD8 T cell responses induced by the PSNPs-KI conjugated group,
albeit significant compared to media alone (p< 0.0001), and cross
reactive CD8 T cell activity was not detectable (Figure 4A).
A boost immunization enhanced the KI specific IFN-γ
response to the PSNPs-KI group approximately threefold larger
compared to one immunization, with a slight boost to the small
cross reactive responses, resulting in the detection of significant
responses also to RI (p < 0.001), and AI (p < 0.01, Figure 4B),
compared to media alone. Overall little cross reactivity was seen
to the APL variants (Figure 4B), albeit the ranking of cross
reactivity to the different variants remained consistent, regarding
side chain charge, to that seen with Montanide and ex vivo pulsed
DCs. Also consistent with previous findings, the peptide needed
to be conjugated to the PSNPs to elicit a response, as the peptide
alone or peptide mixed with PSNPs did not induce detectable
KI specific or cross reactive responses after a single or boost
immunization (Figures 4A,B).
The APL DI Conjugated to PSNPs
Induces a Broader Pattern of Cross
Reactive Responses Compared to that
Induced by the Other Variants
Across the previous adjuvants examined the most cross reactivity
was observed to APLs carrying a positive or neutral side
chain charge. The lowest levels of cross reactive responses were
consistently seen to the APLs carrying a negative charged residue
at position 8, namely EI and DI. To test whether one of the
APL variants could possibly enhance the peptide specific or cross
reactive responses, we further conjugated each APL to PSNPs
using the method described previously, and examined the pattern
of response by IFN-γ ELISpot 13 days after one immunization.
Nanovaccine formulations were chosen as the preferred carrier
system, to investigate whether an improvement in cross reactivity
could be seen when immunizing with a variant compared to
the index KI. Furthermore, there are advantages to using non-
inflammatory adjuvants/carriers in vaccine formulations.
Consistent with previous data, after one immunization
the PSNPs-KI immunized group showed significant IFN-γ
production to the KI epitope (p < 0.0001, Figure 5), however,
no significant cross reactive responses were observed to other
variants. Immunization with PSNPs-RI induced significant self-
reactive responses to RI, as well as significant cross reactivity
to KI (p < 0.0001). PSNPs-VI induced reactivity to VI, and
cross reactivity to AI (p < 0.0001), but no cross reactivity to KI.
Likewise immunizing with PSNPs-AI showed no reactivity to the
index KI, or any other epitope, besides significant reactivity to
itself (p < 0.0001). Interestingly, the PSNPs-EI group induced
significant CD8 T cell responses to EI itself (p < 0.0001), as
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FIGURE 5 | Antigen specific and cross reactive CD8 T cell responses induced by APL conjugated PSNPs. BALB/c mice were immunized once with the
conjugated APLs SYIPSAEKI (25 µg peptide, 0.76% PSNPs/mouse), SYIPSAERI (25 µg peptide, 0.65% PSNPs/mouse), SYIPSAEVI (25 µg peptide, 0.86%
PSNPs/mouse), SYIPSAEAI (25 µg peptide, 1.09% PSNPs/mouse), SYIPSAEEI (25 µg peptide, 1.47% PSNPs/mouse), and SYIPSAEDI (25 µg peptide, 1.02%
PSNPs/mouse) conjugated to PSNPs. Thirteen days after the immunization splenocytes were harvested and antigen specific or cross reactive IFN-γ production was
measured via ELISpot assay. Data shown as mean ± SD of SFU/million cells (pooled cells from 3 mice per group) from triplicate wells. ∗p < 0.05, ∗∗∗p < 0.001,
∗∗∗∗p < 0.0001.
well as DI (p < 0.001), and AI (p < 0.05), but no significant
responses were detected to VI, RI, or KI. Surprisingly, PSNPs-DI
immunization induced significant reactivity to DI (p < 0.001),
and cross -reactivity to AI (p < 0.001), RI (p < 0.0001), and
KI (p < 0.0001), with the response to KI even greater than that
to DI itself. Of the variants tested, only two, RI and DI, were
identified as being cross-reactive to the index peptide epitope
KI in addition to the response to the priming epitope itself.
This implies a ‘one-way’ cross reactivity, where PSNPs-KI cannot
induce a significant cross reactive response to DI or RI after
one immunization, though conversely, PSNPs-DI and PSNPs-RI
can induce a cross reactive response to KI. Overall, PSNPs-DI
induced a substantially different pattern of cross-reactivity, to RI,
AI, and KI, after one immunization compared to the responses
induced by the other conjugated APLs. It would be of interest to
investigate in future the breadth of response to DI incorporated
with other powerful adjuvant systems, considering that in this
study the adjuvant system employed did not substantially alter
reactivity, though impacted the overall magnitude of response.
DISCUSSION
The current study presents an in vivo model to investigate
how polymorphism and variability in protective CD8 T cell
epitopes from infectious pathogens, such as malaria, can possibly
limit the ability of the vaccines to eradicate them. We have
focused on modifications of amino acid position 8 of the
protective CD8 T cell epitope of P. berghei, KI, since this position
has been previously demonstrated to physically interact with
affinity modulating regions of a cognate T cell receptor (TCR;
Maryanski et al., 1993; Kessler et al., 1998; Guillaume et al.,
2003). Furthermore, modifications at this amino-acid position
did not alter binding affinity to the MHCI molecule (Figure 2).
This model was therefore used to investigate for the first time
whether the use of different adjuvants, including conventional
inflammation promoting adjuvants and novel non-inflammatory
nanoparticle based carrier systems, could broaden the repertoire
of T cells induced by vaccines. Additionally, we explored whether
these adjuvants could potentially be used to generate broad
patterns of cross-reactivity capable of recognizing populations of
highly variable pathogens, simulating those naturally present in
malaria endemic regions.
Vaccination with the immunodominant CD8 T cell epitope
KI indicated that reactivity to APLs was unable to be enhanced
by the various adjuvant systems. The results showed that the
induced responses were largely specific to the immunizing KI
epitope itself, with only limited cross-reactivity observed to other
variants. The low to moderate level of reactivity that was observed
to variant epitopes of KI was not due to a simple lack of binding
ability, as all tested variants bound as strongly, or even stronger, to
MHCI than the index peptide KI. The cross reactivity of KI was
focused primarily on the variant RI, which was the most highly
related variant to KI (both positively charged at position 8).
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Furthermore, the KI induced responses failed to elicit substantial
cross-reactivity to other variants with a neutral (AI and VI)
or negative (EI and DI) charge at position 8, regardless of
the adjuvant systems used. Cross-reactive responses, when
found, were directly related to the magnitude of the immune
response induced to the index KI T cell epitope. Importantly,
there was no direct relationship between the intrinsic nature
of the adjuvant system being utilized, whether this was
based on vaccines with water-in-oil emulsions (Montanide),
‘danger signals’ (Poly I:C), non-inflammatory nano-carriers
(PSNPs) or ex vivo peptide pulsed DCs. These data sets
indicate that for vaccines to be truly broadly cross reactive,
it is necessary to look beyond enhancing the magnitude of
the index response. Simply modifying the type of adjuvant
is unlikely to modify the process of priming or boosting
immunity sufficiently to provide broad cross reactive immune
responses.
The fact that DI and EI were unable to elicit strong effector
T cell reactivity in vitro, from cells primed with KI, could
indicate that the naïve T cell repertoire of the animals was
inherently limited in recognizing such variants, for example,
due to holes in the TCR repertoire produced from cross
reactivity to self-antigens. Alternatively, it could have meant
that these variants may be immunogenic themselves, but did
not cross react with KI because their recognition requires a
different set of TCRs from that induced by these variants.
To distinguish between these possibilities, we immunized with
each APL conjugated to the nanoparticle vaccine carrier PSNPs.
What we found was that EI and DI were indeed immunogenic,
eliciting antigen specific T cells, and hence the inability of KI
to induce cross reactive responses was not due to holes in
the TCR repertoire. Moreover, DI was capable of inducing a
broader pattern of T cell reactivity, inducing KI specific CD8
T cells to comparable, or even higher levels as to its own
DI specific T cells. This “one-way” cross reactivity observation
was specific to the DI and RI variants, whilst the other
immunized APLs predominantly induced homologous responses
to the immunization peptide itself. Though RI immunized mice
elicited CD8 T cell reactivity to RI and KI, DI immunized
mice were the only group capable of inducing cross-reactive
responses that were broader than the antigen specific and index
peptide reactive responses induced to the immunized epitope.
There are intriguing consequences to the identification of the
existence of one-directional cross reactivity. For polymorphic
pathogens, it suggests that some natural variants may have
the advantage of not being recognized by immune responses
induced by other variants, whilst being able themselves to
elicit immunity which eliminates other strains in the same
populations.
For vaccine development, these findings show it may be
possible in future to rationally re-engineer polymorphic antigens
to enable them to recognize multiple relevant variants in a
given population of pathogens. Thus acknowledging the fact
that there is extensive research required before the use of re-
engineered polymorphic antigens can commonly be used in
vaccine design, especially for malaria vaccine development, which
already carries a host of inherent challenges. Moreover, although
murine models cannot directly be applied to human studies,
the basic knowledge and understanding of interactions between
APLs and reactivity induced by modifying the peptide, or by
using various adjuvant systems, could be tested against known
human variants. Importantly, this study has shown that for
vaccine design it is relevant to consider immune responses
elicited to APLs, and that it is possible to alter the response by
modifying polymorphic epitopes, instead of simply varying the
adjuvant system used. Given that broader responses were only
seen with certain variants, it would be crucial to screen potential
targets for their reactivity to evaluate their value as a vaccine
candidate. We envisage such approaches would be able to be
taken to tackle the many polymorphic pathogens for which there
are still no effective broadly reactive vaccines, and particularly
help the development of potent liver-stage malaria vaccines.
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